Week in Review: Two China Affiliated Biopharmas Raise $585 Million in IPOs

Deals and Financings   LianBio, a Princeton-Shanghai company, raised $325 million in its US IPO at a market capitalization of $1.9 billion to support its drug in-licensings for  China ; Beijing Clover Biopharma completed a $260 million IPO in  Hong kong to advance its Trimer-Tag™ products including a COVID-19 vaccine;   Beijing BeiGene made a $45 million upfront payment in a deal to partner four natural killer-based cell therapies with  San Diego 's Shoreline Biosciences; Chengdu 's HitGen formed a strategic alliance with Cambridge Molecular of the  UK  to offer CM's DeepDELve 2 pipeline to identify ligands for drug targets; A HitGen subsidiary formed a new company to inhibitors for oncology targets based on innovative science from the labs of University of  Copenhagen  researchers; CANbridge, a  Beijing  rare disease biopharma, announced a two-year sponsored gene therapy research agreement for Duchenne disease with University of  Washington researchers;  Trials and Approvals   Shanghai Junshi Bio and its  US  partner Coherus Bio reported they have filed for US approval of Junshi's PD-1; TransThera Sciences ( Nanjing ) was granted US Fast Track Designation for its Phase II Cholangiocarcinoma therapy; Suzhou Kintor Pharma began a Phase Ib/II trial of its ALK-1 antibody in combination with Alphamab's PD-L1/CTLA-4 bispecific antibody; Shanghai Antengene reported it was approved to start US trials of a bi-specific mAb for solid tumors and B-cell non-Hodgkin's lymphoma.  Stock Symbols: (NSDQ: LIAN) (HK: 1297) (NSDQ: BGNE; HK: 06160) (SHA: 688222) (HK: 1877; SSE: 688180) (NSDQ: CHRS) (HK: 9939) (HK: 6996)